Lucid Diagnostics completes $18.16M Series B Preferred offering and exchange of Series A/A-1 shares

Lucid Diagnostics Inc.

Gross proceeds of $18.16M: $12.495M from new subscriptions and $5.67M from Series A-1 sales immediately exchanged.
Series B Preferred convertible at $1.2444 per share; mandatory conversion on Mar 13, 2026 or if VWAP >$8 for 20 of 30 days.
Annual dividends: 20% of conversion shares on Mar 13, 2025 and Mar 13, 2026; accelerated on fundamental transactions.
Beneficial ownership limited to 4.99% (or 9.99% at holder election); primary market cap of 19.99% of outstanding common.
All outstanding Series A and A-1 Preferred exchanged; 44,285 Series B shares outstanding after close.

item 3.02 item 3.03 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Lucid Diagnostics Inc.: 公司修订了公司章程，授权发行最多20,000,000股优先股，并通过系列B指定证书和系列A-1修订证书分别指定了系列B优先股和增加系列A-1优先股数量。.

Change: charter amendment

Exact text from the filing

The Amended and Restated Certificate of Incorporation of the Company authorizes the issuance of up to 20,000,000 shares of preferred stock, par value $0.001 per share, and further authorizes the Board of the Company to fix and determine the designation, preferences, conversion rights, or other rights, including voting rights, qualifications, limitations, or restrictions of the preferred stock. The Series B Certificate of Designation designates up to 56,000 of the shares of preferred stock as Series B Preferred Stock and the Series A-1 Certificate of Amendment increases the number of shares designated as Series A-1 Preferred Stock by 5,670 shares.

View on SEC.gov

261 governance changes filed in the last 30 days. Browse all governance changes →

Lucid Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-009895

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.